OBJECTIVE: We analyze the factors related to progression to AIDS or death in HIV-infected patients from the Proyecto para la Informatización del Seguimiento Clínico epidemiológico de los pacientes con Infección por VIH/SIDA (PISCIS) Cohort and we assess the optimal time to initiate highly active antiretroviral therapy (HAART) taking lead time into account. METHODS: We selected naive patients who were AIDS-free and initiated HAART after January 1998. Statistical analyses were performed using Cox proportional hazards models. Lead time was defined as the time it took the deferred group with an early disease stage to reach the later stage. The analysis accounting for lead time was performed using multiple imputation methods based on estimates from the pre-HAART period as described elsewhere. RESULTS: Multivariate analysis on 2035 patients (median follow-up = 34.3 months) showed significantly higher hazard ratios (HRs) for a CD4 count <200 cells/microL (HR = 3.79, 95% confidence interval [CI]: 2.18 to 6.57), HIV-1 RNA level >100,000 copies/mL (HR = 1.84, 95% CI: 1.26 to 2.69), and hepatitis C virus (HCV) coinfection (HR = 2.40, 95% CI: 1.65 to 3.49), whereas a lower risk was found for those who started HAART between January 2001 and June 2004 (HR = 0.55, 95% CI: 0.30 to 0.90). When lead time and unseen events were included, we found a higher risk of progression to AIDS among patients who deferred treatment when the CD4 count reached <200 cells/microL (HR = 2.97, 95% CI: 1.91 to 4.63) and 200 to 350 cells/microL (HR = 1.85, 95% CI: 1.03 to 3.33) compared with those who started treatment with CD4 counts from 200 to 350 cells/microL and >350 cells/microL, respectively. CONCLUSIONS: Advanced HIV disease, HCV coinfection, and early HAART period were determinants of AIDS progression or death. Lead-time analysis in asymptomatic HIV-infected patients suggests that the best time to start HAART is before the CD4 count falls to lower than 350 cells/microL.
OBJECTIVE: We analyze the factors related to progression to AIDS or death in HIV-infectedpatients from the Proyecto para la Informatización del Seguimiento Clínico epidemiológico de los pacientes con Infección por VIH/SIDA (PISCIS) Cohort and we assess the optimal time to initiate highly active antiretroviral therapy (HAART) taking lead time into account. METHODS: We selected naive patients who were AIDS-free and initiated HAART after January 1998. Statistical analyses were performed using Cox proportional hazards models. Lead time was defined as the time it took the deferred group with an early disease stage to reach the later stage. The analysis accounting for lead time was performed using multiple imputation methods based on estimates from the pre-HAART period as described elsewhere. RESULTS: Multivariate analysis on 2035 patients (median follow-up = 34.3 months) showed significantly higher hazard ratios (HRs) for a CD4 count <200 cells/microL (HR = 3.79, 95% confidence interval [CI]: 2.18 to 6.57), HIV-1 RNA level >100,000 copies/mL (HR = 1.84, 95% CI: 1.26 to 2.69), and hepatitis C virus (HCV) coinfection (HR = 2.40, 95% CI: 1.65 to 3.49), whereas a lower risk was found for those who started HAART between January 2001 and June 2004 (HR = 0.55, 95% CI: 0.30 to 0.90). When lead time and unseen events were included, we found a higher risk of progression to AIDS among patients who deferred treatment when the CD4 count reached <200 cells/microL (HR = 2.97, 95% CI: 1.91 to 4.63) and 200 to 350 cells/microL (HR = 1.85, 95% CI: 1.03 to 3.33) compared with those who started treatment with CD4 counts from 200 to 350 cells/microL and >350 cells/microL, respectively. CONCLUSIONS: Advanced HIV disease, HCV coinfection, and early HAART period were determinants of AIDS progression or death. Lead-time analysis in asymptomatic HIV-infectedpatients suggests that the best time to start HAART is before the CD4 count falls to lower than 350 cells/microL.
Authors: Andrew J Levine; Susan Service; Eric N Miller; Sandra M Reynolds; Elyse J Singer; Paul Shapshak; Eileen M Martin; Ned Sacktor; James T Becker; Lisa P Jacobson; Paul Thompson; Nelson Freimer Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-05-24 Impact factor: 3.568
Authors: C M J Drapeau; A Pan; C Bellacosa; G Cassola; M P Crisalli; M De Gennaro; S Di Cesare; F Dodi; G Gattuso; L Irato; P Maggi; M Pantaleoni; P Piselli; L Soavi; E Rastrelli; E Tacconelli; N Petrosillo Journal: Infection Date: 2009-10 Impact factor: 3.553
Authors: Reuben Granich; Siobhan Crowley; Marco Vitoria; Caoimhe Smyth; James G Kahn; Rod Bennett; Ying-Ru Lo; Yves Souteyrand; Brian Williams Journal: Curr Opin HIV AIDS Date: 2010-07 Impact factor: 4.283
Authors: Emilie Lanoy; Margaret May; Amanda Mocroft; Andrew Phillip; Amy Justice; Geneviève Chêne; Hansjakob Furrer; Timothy Sterling; Antonella D'Arminio Monforte; Lluís Force; John Gill; Ross Harris; Robert S Hogg; Jürgen Rockstroh; Mike Saag; Pavel Khaykin; Frank de Wolf; Jonathan A C Sterne; Dominique Costagliola Journal: AIDS Date: 2009-10-23 Impact factor: 4.177
Authors: Maile Ray; Roger Logan; Jonathan A C Sterne; Sonia Hernández-Díaz; James M Robins; Caroline Sabin; Loveleen Bansi; Ard van Sighem; Frank de Wolf; Dominique Costagliola; Emilie Lanoy; Heiner C Bucher; Viktor von Wyl; Anna Esteve; Jordi Casbona; Julia del Amo; Santiago Moreno; Amy Justice; Joseph Goulet; Sara Lodi; Andrew Phillips; Rémonie Seng; Laurence Meyer; Santiago Pérez-Hoyos; Patricia García de Olalla; Miguel A Hernán Journal: AIDS Date: 2010-01-02 Impact factor: 4.177
Authors: Reuben Granich; Siobhan Crowley; Marco Vitoria; Ying-Ru Lo; Yves Souteyrand; Christopher Dye; Charlie Gilks; Teguest Guerma; Kevin M De Cock; Brian Williams Journal: J Int AIDS Soc Date: 2010-01-12 Impact factor: 5.396